Our Q2 Hedge Fund data is now updated! A few favorite stocks are lining up for major readouts in Q3–Q4, and some are likely to move big. Below are 6 key catalysts we’re watching closely. 📈 📉   $ MLTX  Sonelokimab / Hidradenitis Suppurativa / Phase 3 » Potential for a highly differentiated, “gold standard” therapy in HS » Achieved highest responses to date in HS » Ph2 MIRA trial in HS was designed as a pivotal study Ph2 results recap 👇 $ CRNX  Paltusotine / Acromegaly / PDU

Our Q2 Hedge Fund data is now updated! A few favorite stocks are lining up for major readouts in Q3–Q4, and some are likely to move big.

As we reached the end of June last week, we review moves from smid-cap biopharma companies during the month of June. See Table 1 for...

As we begin June, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for...

$XBI $69.18 | -2.85% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #CYCN +8.6%...

$XBI $69.18 | -2.85% Table of Contents: Covid Updates Pipeline Updates Business Updates Covid Updates # Pipeline Updates #CYCN +8.6%...